Platinum-based neoadjuvant chemotherapy followed by radical surgery for cervical carcinoma international federation of gynecology and obstetrics stage IB2-IIB

Lucas Minig, Nicoletta Colombo, Vanna Zanagnolo, Fabio Landoni, Luca Bocciolone, José Miguel Cárdenas-Rebollo, Simona Iodice, Angelo Maggioni

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: The objective of this study was to determine the response rate to chemotherapy, as well as the progression-free survival (PFS), the overall survival (OS), and the main prognostic factors in patients treated at the European Institute of Oncology in Milan, Italy. Methods: Retrospective data were collected on patients with uterine cervical carcinoma, International Federation of Gynecology and Obstetrics (FIGO) stage IB2 to IIB, who underwent platinum-based neoadjuvant chemotherapy (NACT) followed by radical hysterectomy. Results: A total of 121 patients were studied. The median (range) age was 45 years old (23-69 years). The distribution of patients by International Federation of Gynecology and Obstetrics stage was as follows: n = 88 (73%) with stage IB2, n = 7 (6%) with stage IIA, and n = 26 (21%) with stage IIB. The median (range) tumor size was 50 mm (20-90 mm). Neoadjuvant chemotherapy involved a combination of cisplatin, paclitaxel, and ifosfamide in 80 patients (65%). Using this treatment, 112 patients (93%) received 3 cycles of NACT, whereas 6 (5%) received 4 cycles. Complete and partial pathology response was observed in 9 patients (7%) and 79 patients (66%), respectively. Adjuvant radiotherapy was not necessary in 65% of patients. A 5-year PFS and OS of 58% and 71%, respectively, were observed. Independent prognostic factors for PFS and OS were identified, including response to NACT, persistent lymph node metastases, and parametrial involvement. Conclusions: Neoadjuvant chemotherapy in this group of tumors is a promising treatment strategy and should be discussed with patients. Although these results are comparable to those obtained by standard chemoradiation treatment, one strategy should not be recommended over the other until the results of the ongoing phase 3 trial for NACT are released.

Original languageEnglish
Pages (from-to)1647-1654
Number of pages8
JournalInternational Journal of Gynecological Cancer
Volume23
Issue number9
DOIs
Publication statusPublished - 2013

Fingerprint

Platinum
Gynecology
Obstetrics
Carcinoma
Drug Therapy
Disease-Free Survival
Survival
Ifosfamide
Adjuvant Radiotherapy
Hysterectomy
Italy
Neoplasms
Therapeutics
Lymph Nodes
Pathology
Neoplasm Metastasis

Keywords

  • Locally advanced uterine cervical cancer
  • Platinum-based neoadjuvant chemotherapy
  • Radical hysterectomy

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Platinum-based neoadjuvant chemotherapy followed by radical surgery for cervical carcinoma international federation of gynecology and obstetrics stage IB2-IIB. / Minig, Lucas; Colombo, Nicoletta; Zanagnolo, Vanna; Landoni, Fabio; Bocciolone, Luca; Cárdenas-Rebollo, José Miguel; Iodice, Simona; Maggioni, Angelo.

In: International Journal of Gynecological Cancer, Vol. 23, No. 9, 2013, p. 1647-1654.

Research output: Contribution to journalArticle

@article{c92cc74e0339406aa16ce79f72a06411,
title = "Platinum-based neoadjuvant chemotherapy followed by radical surgery for cervical carcinoma international federation of gynecology and obstetrics stage IB2-IIB",
abstract = "Objective: The objective of this study was to determine the response rate to chemotherapy, as well as the progression-free survival (PFS), the overall survival (OS), and the main prognostic factors in patients treated at the European Institute of Oncology in Milan, Italy. Methods: Retrospective data were collected on patients with uterine cervical carcinoma, International Federation of Gynecology and Obstetrics (FIGO) stage IB2 to IIB, who underwent platinum-based neoadjuvant chemotherapy (NACT) followed by radical hysterectomy. Results: A total of 121 patients were studied. The median (range) age was 45 years old (23-69 years). The distribution of patients by International Federation of Gynecology and Obstetrics stage was as follows: n = 88 (73{\%}) with stage IB2, n = 7 (6{\%}) with stage IIA, and n = 26 (21{\%}) with stage IIB. The median (range) tumor size was 50 mm (20-90 mm). Neoadjuvant chemotherapy involved a combination of cisplatin, paclitaxel, and ifosfamide in 80 patients (65{\%}). Using this treatment, 112 patients (93{\%}) received 3 cycles of NACT, whereas 6 (5{\%}) received 4 cycles. Complete and partial pathology response was observed in 9 patients (7{\%}) and 79 patients (66{\%}), respectively. Adjuvant radiotherapy was not necessary in 65{\%} of patients. A 5-year PFS and OS of 58{\%} and 71{\%}, respectively, were observed. Independent prognostic factors for PFS and OS were identified, including response to NACT, persistent lymph node metastases, and parametrial involvement. Conclusions: Neoadjuvant chemotherapy in this group of tumors is a promising treatment strategy and should be discussed with patients. Although these results are comparable to those obtained by standard chemoradiation treatment, one strategy should not be recommended over the other until the results of the ongoing phase 3 trial for NACT are released.",
keywords = "Locally advanced uterine cervical cancer, Platinum-based neoadjuvant chemotherapy, Radical hysterectomy",
author = "Lucas Minig and Nicoletta Colombo and Vanna Zanagnolo and Fabio Landoni and Luca Bocciolone and C{\'a}rdenas-Rebollo, {Jos{\'e} Miguel} and Simona Iodice and Angelo Maggioni",
year = "2013",
doi = "10.1097/IGC.0b013e3182a616d2",
language = "English",
volume = "23",
pages = "1647--1654",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Platinum-based neoadjuvant chemotherapy followed by radical surgery for cervical carcinoma international federation of gynecology and obstetrics stage IB2-IIB

AU - Minig, Lucas

AU - Colombo, Nicoletta

AU - Zanagnolo, Vanna

AU - Landoni, Fabio

AU - Bocciolone, Luca

AU - Cárdenas-Rebollo, José Miguel

AU - Iodice, Simona

AU - Maggioni, Angelo

PY - 2013

Y1 - 2013

N2 - Objective: The objective of this study was to determine the response rate to chemotherapy, as well as the progression-free survival (PFS), the overall survival (OS), and the main prognostic factors in patients treated at the European Institute of Oncology in Milan, Italy. Methods: Retrospective data were collected on patients with uterine cervical carcinoma, International Federation of Gynecology and Obstetrics (FIGO) stage IB2 to IIB, who underwent platinum-based neoadjuvant chemotherapy (NACT) followed by radical hysterectomy. Results: A total of 121 patients were studied. The median (range) age was 45 years old (23-69 years). The distribution of patients by International Federation of Gynecology and Obstetrics stage was as follows: n = 88 (73%) with stage IB2, n = 7 (6%) with stage IIA, and n = 26 (21%) with stage IIB. The median (range) tumor size was 50 mm (20-90 mm). Neoadjuvant chemotherapy involved a combination of cisplatin, paclitaxel, and ifosfamide in 80 patients (65%). Using this treatment, 112 patients (93%) received 3 cycles of NACT, whereas 6 (5%) received 4 cycles. Complete and partial pathology response was observed in 9 patients (7%) and 79 patients (66%), respectively. Adjuvant radiotherapy was not necessary in 65% of patients. A 5-year PFS and OS of 58% and 71%, respectively, were observed. Independent prognostic factors for PFS and OS were identified, including response to NACT, persistent lymph node metastases, and parametrial involvement. Conclusions: Neoadjuvant chemotherapy in this group of tumors is a promising treatment strategy and should be discussed with patients. Although these results are comparable to those obtained by standard chemoradiation treatment, one strategy should not be recommended over the other until the results of the ongoing phase 3 trial for NACT are released.

AB - Objective: The objective of this study was to determine the response rate to chemotherapy, as well as the progression-free survival (PFS), the overall survival (OS), and the main prognostic factors in patients treated at the European Institute of Oncology in Milan, Italy. Methods: Retrospective data were collected on patients with uterine cervical carcinoma, International Federation of Gynecology and Obstetrics (FIGO) stage IB2 to IIB, who underwent platinum-based neoadjuvant chemotherapy (NACT) followed by radical hysterectomy. Results: A total of 121 patients were studied. The median (range) age was 45 years old (23-69 years). The distribution of patients by International Federation of Gynecology and Obstetrics stage was as follows: n = 88 (73%) with stage IB2, n = 7 (6%) with stage IIA, and n = 26 (21%) with stage IIB. The median (range) tumor size was 50 mm (20-90 mm). Neoadjuvant chemotherapy involved a combination of cisplatin, paclitaxel, and ifosfamide in 80 patients (65%). Using this treatment, 112 patients (93%) received 3 cycles of NACT, whereas 6 (5%) received 4 cycles. Complete and partial pathology response was observed in 9 patients (7%) and 79 patients (66%), respectively. Adjuvant radiotherapy was not necessary in 65% of patients. A 5-year PFS and OS of 58% and 71%, respectively, were observed. Independent prognostic factors for PFS and OS were identified, including response to NACT, persistent lymph node metastases, and parametrial involvement. Conclusions: Neoadjuvant chemotherapy in this group of tumors is a promising treatment strategy and should be discussed with patients. Although these results are comparable to those obtained by standard chemoradiation treatment, one strategy should not be recommended over the other until the results of the ongoing phase 3 trial for NACT are released.

KW - Locally advanced uterine cervical cancer

KW - Platinum-based neoadjuvant chemotherapy

KW - Radical hysterectomy

UR - http://www.scopus.com/inward/record.url?scp=84888337835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888337835&partnerID=8YFLogxK

U2 - 10.1097/IGC.0b013e3182a616d2

DO - 10.1097/IGC.0b013e3182a616d2

M3 - Article

C2 - 24100590

AN - SCOPUS:84888337835

VL - 23

SP - 1647

EP - 1654

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 9

ER -